Patients with the MetB subtype had shorter cancer‐specific survival after ADT than MetA and MetC patients (median survival 25 vs. 49 months, respectively, P = 0.030, Fig. 1E), and lower serum PSA levels compared to MetA patients at diagnosis (0.28‐fold, P = 0.011) and borderline at Met surgery (Table 1). This evidence concerns the gene KLK3 and cancer.